Introduction. Previous research has demonstrated that nonsteroidal anti-inflammatory
agents alter the incidence of colorectal cancer. It has been postulated that the response may …

According to WHO statistics, in 1996 875,000 new cases of colorectal cancer were
diagnosed and 495,000 deaths were attributed to it worldwide (1). It is the third most …

The evidence that cyclooxygenase‐2 (COX‐2) is upregulated and plays an important role in
carcinogenesis of gastric cancer has triggered the topic of COX‐2 inhibitors as …

Background: Numerous studies have demonstrated that the levels of prostaglandins are
greater in various cancers, including breast cancer and colon cancer, than in normal tissues …

Colorectal cancer (CRC) leads to approximately 550,000 annual deaths worldwide and is
thus a major public health concern [1]. Once an individual is diagnosed with CRC, the …

Abstract As with cyclooxygenase (COX)‐2, genetic disruption of COX‐1 gene or
pharmacologic inhibition of its activity has been shown to decrease the number of intestinal …

Clinical and preclinical studies provide strong evidence that nonsteroidal anti-inflammatory
drugs (NSAIDs) can prevent numerous types of cancers, especially colorectal cancer …

It is proposed that non-steroidal anti-inflammatory drugs (NSAIDs) reduce colorectal
tumorigenesis by inhibition of cyclooxygenase (COX). COX is a key enzyme in the …

The cyclooxygenase (COX) family of enzymes has been implicated in cell proliferation and
angiogenesis in many tumors, including colon cancer. Indeed, cyclooxygenase-2 (COX-2) …

There is a wealth of evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) can
prevent colorectal cancer. In this article the role of cyclooxygenase 1 and 2, the principle …